The decision puts Travere and CSL in line for a first-in-class approval in IgAN for sparsentan, an oral antagonist of both endothelin type A (ETA) and angiotensin II subtype 1 (AT1) receptors ...

Angiotensin II (AT-II)-Receptor Antagonists are Reviewed. Research focused on blocking the renin- angiotensin system (RAS) led to the discovery of angiotensin-converting-enzyme (ACE) inhibitors ...

Of the AT-II-receptor antagonists, only candesartan has any clinically important interactions with digoxin, warfarin, and hydrochlorothiazide. Candesartan may increase serum concentrations of ...

You need to be a subscriber to view this content.

Department of Chemical Sciences, Indian Institute of Science Education and Research (IISER) Mohali, Knowledge City, Sector 81, SAS Nagar, Mohali, Manauli P.O., Punjab 140306, India ...